U.S. Markets close in 4 hrs 25 mins
  • S&P 500

    4,376.46
    +18.73 (+0.43%)
     
  • Dow 30

    34,101.41
    +130.94 (+0.39%)
     
  • Nasdaq

    14,813.75
    +99.84 (+0.68%)
     
  • Russell 2000

    2,182.86
    +0.66 (+0.03%)
     
  • Crude Oil

    70.01
    -0.28 (-0.40%)
     
  • Gold

    1,781.70
    +17.90 (+1.01%)
     
  • Silver

    22.53
    +0.37 (+1.68%)
     
  • EUR/USD

    1.1722
    -0.0005 (-0.0469%)
     
  • 10-Yr Bond

    1.3070
    -0.0020 (-0.15%)
     
  • Vix

    24.45
    -1.26 (-4.90%)
     
  • GBP/USD

    1.3651
    -0.0008 (-0.0614%)
     
  • USD/JPY

    109.2990
    -0.1210 (-0.1106%)
     
  • BTC-USD

    44,590.88
    -3,435.44 (-7.15%)
     
  • CMC Crypto 200

    1,067.81
    +3.97 (+0.37%)
     
  • FTSE 100

    6,969.72
    +65.81 (+0.95%)
     
  • Nikkei 225

    29,839.71
    -660.34 (-2.17%)
     

Pharming Group reports financial results for the first quarter of 2021

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·15 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Results impacted by effects of COVID-19 in the US; recovery towards the end of Q1 2021 with expected return to growth in Q2 2021

LEIDEN, Netherlands, May 13, 2021 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) presents its (unaudited) financial report for the first quarter of the year ended 31 March 2021. As previously announced, as of 1 January 2021, Pharming changed its presentation currency from Euro to US Dollars.

Pharming Group N.V. logo
Pharming Group N.V. logo
  • The Company will hold an analyst conference call at 13.30 CET/07.30 EST today. Dial in details can be found on page 6 of this report

Financial Summary





Amounts in US $m except per share data

Q1 2021

Q1 2020

% change





Consolidated Income Statement




Revenues

43.6

54.5

-20%

Gross profit

38.7

48.5

-20%

Operating result

6.3

21.5

-71%

Finance cost, net

6.6

-7.8

-184%

Income tax expense

-4.3

-4.4

-3%

Net result

8.5

9.3

-9%

Consolidated Balance Sheet




Cash & marketable securities
(Including restricted cash)

208.5

149.4

40%

Share Information




Basic earnings per share (€)

0.013

0.015

-12,6%

Diluted earnings per share (€)

0.013

0.013

-0,8%

Financial highlights

  • Revenues for the first quarter of 2021 decreased by 20% to $43.6 million compared to $54.5 million in Q1 2020. As previously announced, the progression of the COVID-19 pandemic has resulted in quarterly fluctuations in revenue due to ongoing effects on access to customers and phasing of ordering patterns. In the US, there was a surge in COVID-19 cases at the end of 2020 and into 2021, which led to some patients pre-filling of RUCONEST® prescriptions in Q4 2020. It also resulted in the temporary closure of the majority of physician offices causing a reduction in routine and diagnostic patient visits and a slow-down of annual renewals of prescriptions. The combination of these factors led to lower prescription refill rates by patients still using their additional RUCONEST® stock from Q4 2020 and a reduction in new patient enrollments in the first part of Q1 2021. Towards the end of Q1 2021, these trends started to reverse, with a significant increase in new patient enrollment. In Europe, demand remained stable, but growth was also impacted by a similar chain of events seen in the US caused by COVID-19.

  • Gross profit decreased 20% to $38.7 million (Q1 2020: $48.5 million), mainly due to the decrease in sales in the US.

  • Operating profit decreased to $6.3 million (Q1 2020: $21.5 million), mainly as a result of the decrease in revenues and an increase in operating expenses from $27.3 million in Q1 2020 to $32.7 million in Q1 2021. This increase was a combination of launch preparation and manufacturing cost for leniolisib ($2.7 million), a significant increase in cost of insurances ($1.0 million), an increase in share-based compensation of $1.1 million and increased compliance and control costs.

  • Net profit of $8.5 million decreased 9% (Q1 2020: $9.3 million). The decrease was limited as a result of a significant decrease in finance costs from $7.8 million in Q1 2020 to a $6.6 million gain in Q1 2021, mainly due to the successful refinancing in 2020 and the gains in the US Dollar/Euro exchange rate on the US Dollar denominated flexible deposits, including short-maturing US Treasury stocks.

  • Positive cashflows from operations amounted to $7.1 million in Q1 2021. Cash and cash equivalents increased by $1.5 million to $206.6 million from $205.2 million at the end of Q4 2020. Cash and cash equivalents at the end of Q1 2020 were $149.4 million.

  • The equity position improved from $183.4 million at the end of Q4 2020 to $186.4 million at the end of Q1 2021 (Q1 2020: $126.9 million). The majority of the increase in equity is related to the net result for Q1 2021.

  • Inventories increased slightly from $21.2 million at the end of Q4 2020 to $21.8 million at the end of Q1 2021.

  • Since the last reporting date of 6 April 2021, the Company has issued 3,406,250 shares in connection with exercises of options and long-term incentive plans under the current share-based compensation plan. The number of issued shares as at 13 May 2021 is 644,696,264. The fully diluted number of shares as at 13 May 2021 is 763,632,543.

Operational highlights

  • Launched genetic testing program 'navigateAPDS' in collaboration with Invitae Corporation in the US and Canada to improve genetic testing for activated PI3K delta syndrome (APDS).

  • Announced the intention to nominate three Non-Executive Directors, Steven Baert, Leon Kruimer and Jabine van der Meijs, which completes the required transition in the board after the maximum term of office for certain Non-Executive Directors was reached according to the Dutch Corporate Governance Code.

Post-period operational highlights

  • Initiated enrollment of first patient in multi-center Phase IIb clinical trial of RUCONEST® for the prevention of acute kidney injury after myocardial infarction.

Chief Executive Officer, Sijmen de Vries, commented:

"As previously experienced, the progression of the COVID-19 pandemic has resulted in quarterly fluctuations in revenue. Results in Q1 2021 were negatively affected in the US by a severe COVID-19 surge at the end of 2020 and into 2021.

"This caused overstocking of RUCONEST® in Q4 2020 and physician office closures well into Q1 2021, which resulted in reduced patient visits and slower annual prescription renewals. The combination of these factors in Q1 2021 led to lower prescription refill rates by patients still using additional RUCONEST® stock and a reduction in new patient enrollment.

"Positively, towards the end of Q1 2021, these trends started to reverse. We were also able to resume some face-to-face sales and marketing activities due to the rapid roll-out of COVID-19 vaccinations in the US.

"As a result, we realized a significant increase in new patient enrollment at the end of Q1 2021. This increase has continued into Q2 2021 and we expect sales to continue to recover over the quarter, subject to any further surges in COVID-19 cases.

"Outside of the US, demand remained stable, but growth was affected by travel restrictions and lockdowns still in place in most EU markets.

"In our pipeline, we continued to progress activities for the anticipated launch of leniolisib in Q4 2022, including an important collaboration to offer US immunologists access to free genetic testing for primary immune deficiency patients exhibiting APDS symptoms.

"In addition, post period end, we announced the start of our Phase IIb study in acute kidney injury as we continue to investigate the treatment potential of RUCONEST® in further indications."

Outlook

For the remainder of 2021, the Company expects:

  • Returning to growth of revenues from sales of RUCONEST®, mainly driven by the US and expanded EU operations, subject to the progression of the COVID-19 pandemic and quarterly fluctuations in revenues as a result of the ongoing effects of the pandemic on access to customers and phasing of ordering patterns.

  • Maintenance of positive net earnings during the year, we therefore do not expect to require additional financing to maintain the current business.

  • Investments in acquisitions and in-licensing of new development opportunities and assets, as these occur.

  • Continued investment in the expansion of production of RUCONEST® and production of leniolisib.

  • Investment in pre-marketing activities for leniolisib and the continuing registration-enabling study for leniolisib for APDS, as well as our ongoing clinical trials for rhC1INH and other development activities.

  • Continued close monitoring of the ongoing COVID-19 pandemic and the potential impact on the business. Currently, as a result of halted or slowed recruitment and issues related to disrupted supply chains for patient testing materials and consumables used in manufacturing, timelines for the clinical trials could incur further delays and manufacturing could incur temporary disruptions/ delays.

No further specific financial guidance for 2021 is provided.

As previously announced, as of 1 January 2021, the Company changed its presentation currency from Euro to US Dollar.

About Pharming Group N.V.

Pharming Group N.V. is a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs.

The flagship of our portfolio is our recombinant human C1 esterase inhibitor (rhC1INH) franchise. C1INH is a naturally occurring protein that down regulates the complement and contact cascades in order to control inflammation in affected tissues.

Our lead product, RUCONEST®, is the first and only plasma-free rhC1INH protein replacement therapy. It is approved for the treatment of acute hereditary angioedema (HAE) attacks. We are commercializing RUCONEST® in the United States, the European Union and the United Kingdom through our own sales and marketing organization, and the rest of the world through our distribution network.

In addition, we are investigating the clinical efficacy of rhC1INH in the treatment of further indications, including pre-eclampsia, acute kidney injury and severe pneumonia as a result of COVID-19 infections.

We are also studying our oral precision medicine, leniolisib (a phosphoinositide 3-kinase delta, or PI3K delta, inhibitor), for the treatment of activated PI3K delta syndrome, or APDS, in a registration enabling Phase 2/3 study in the United States and Europe.

Furthermore, we are leveraging our transgenic manufacturing technology to develop next-generation protein replacement therapies, most notably for Pompe disease, which is currently in preclinical development.

For further information please visit: www.pharming.com

Forward-looking Statements

This press release contains forward-looking statements, including with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, Pharming's ability to overcome the challenges posed by the COVID-19 pandemic to the conduct of its business, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that that are described in Pharming's 2020 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release.

Inside Information

This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

For further public information, contact:

Pharming Group, Leiden, The Netherlands
Sijmen de Vries, CEO: T: +31 71 524 7400
Susanne Embleton, Investor Relations Manager: T: +31 71 524 7400 E: investor@pharming.com

FTI Consulting, London, UK
Victoria Foster Mitchell/Alex Shaw/Amy Byrne
T: +44 203 727 1000

LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl

Conference call dial-in information

Please note, the Company will only take questions from dial-in attendees.



Netherlands (Local)

085 888 7233

United Kingdom

0800 640 6441

United Kingdom (Local)

020 3936 2999

United States

1 855 9796 654

United States (Local)

1 646 664 1960

All other locations

+44 20 3936 2999



Access code: 692461


Webcast Link:

https://webcast.openbriefing.com/pharming-q1/

Pharming Group N.V.
Condensed Consolidated Interim Financial Statements in US Dollars (unaudited)
For the period ended 31 March 2021

  • Condensed consolidated statement of profit or loss

  • Condensed consolidated statement of comprehensive income

  • Condensed consolidated balance sheet

  • Condensed consolidated statement of cash flow

Appendix: Main condensed consolidated Interim Financial Statements reported in Euros
(This appendix is not part of the Condensed Consolidated Interim Financial Statements)

  • Condensed consolidated statement of profit or loss in Euros

  • Condensed consolidated statement balance sheet in Euros

  • Condensed consolidated statement of cash flows in Euros

Condensed Consolidated Statement of Profit or Loss

For the period ended 31 March




Amounts in $ '000

YTD 2021

YTD 2020

Revenues

43.564

54.469

Costs of sales

(4.843)

(5.955)

Gross profit

38.721

48.514

Other income

259

267

Research and development

(10.700)

(8.859)

General and administrative

(7.161)

(5.709)

Marketing and sales

(14.836)

(12.725)

Other Operating Costs

(32.697)

(27.293)

Operating profit

6.283

21.488

Fair value loss on revaluation derivatives

30

134

Other finance income

8.159

409

Other finance expenses

(1.598)

(8.378)

Finance cost, net

6.591

(7.835)

Share of net profits in associates using the equity
method

(82)

15

Profit before tax

12.792

13.668

Income tax expense

(4.269)

(4.418)

Profit for the year

8.523

9.250

Basic earnings per share (€)

0,013

0,015

Diluted earnings per share (€)

0,013

0,013

Condensed Consolidated Statement of Comprehensive Income

For the period ended 31 March




Amounts in $ '000

2021

2020

Profit for the year

8.523

9.250

Currency translation differences

(8.483)

(2.631)

Items that may be subsequently reclassified to profit or loss

(8.483)

(2.631)

Other comprehensive income (loss), net of tax

(8.483)

(2.631)

Total comprehensive income for the year

40

6.619

Condensed Consolidated Balance Sheet

For the period ended 31 March




Amounts in $ '000

March 31, 2021

December 31, 2020

Non-current assets



Intangible assets

89.943

94.083

Property, plant and equipment

13.093

12.226

Right-of-use assets

8.828

9.427

Deferred tax assets

27.559

31.877

Investment accounted for using the equity method

6.720

7.118

Restricted cash

863

510

Total non-current assets

147.006

155.241

Current assets



Inventories

21.765

21.157

Trade and other receivables

32.941

35.902

Restricted cash

962

995

Cash and cash equivalents

206.625

205.159

Total current assets

262.293

263.213

Total assets

409.299

418.453




Equity



Share capital

7.195

7.163

Share premium

449.135

444.940

Legal reserves

11.358

19.859

Accumulated deficit

(281.328)

(288.527)

Shareholders' equity

186.360

183.435

Non-current liabilities



Convertible bonds

141.169

149.727

Lease liabilities

7.744

8.230

Other financial liabilities

189

212

Total non-current liabilities

149.102

158.169

Current liabilities



Convertible bonds

3.062

2.040

Derivative financial liabilities

84

181

Trade and other payables

43.682

47.666

Lease liabilities

1.907

1.962

Other financial liabilities

25.103

25.000

Total current liabilities

73.837

76.849

Condensed Consolidated Statement of Cash Flow

For the period ended 31 March




Amounts in $'000

YTD 2021

YTD 2020

Profit before tax

12.792

13.668

Non-cash adjustments:



Depreciation, amortisation, impairment

2.063

1.883

Equity settled share-based payments

1.909

760

Fair value gain (loss) loss on revaluation of derivatives

(30)

(134)

Other finance income

(8.159)

(409)

Other finance expenses

1.598

8.378

Share of net profits in associates using the equity method

(82)

15

Other

(1.094)

(40)

Operating cash flows before changes in working capital

8.997

24.121

Changes in working capital:



Inventories

(608)

(63)

Trade and other receivables

2.961

(5.334)

Payables and other current liabilities

(4.006)

2.761

Restricted cash

(321)

12

Release contract liabilities



Total changes in working capital

(1.974)

(2.624)

Interest received

38

335

Income taxes paid

-

-

Net cash flows generated from (used in) operating activities

7.061

21.832

Capital expenditure for property, plant and equipment

(1.956)

(660)

Investment intangible assets

(460)

(210)

Investment associate

398

8

Acquisition of license

(547)

(6.077)

Net cash flows used in investing activities

(2.565)

(6.939)

Repayment on loans and borrowings

-

(54.965)

Payment on contingent consideration

-

(20.039)

Payment of lease liabilities

(554)

(525)

Proceeds of issued convertible bonds

-

138.124

Transaction costs related to issued convertible bond

-

(2.561)

Interests on loans

(2.266)

(382)

Interests on leases

(234)

-

Proceeds of equity and warrants

674

547

Net cash flows generated from (used in) financing activities

(2.380)

60.199

Increase (decrease) of cash

2.116

75.092

Exchange rate effects

(650)

(2.544)

Cash and cash equivalents at 1 January

205.159

74.348

Total cash and cash equivalents at 31 March

206.625

146.896

Appendix: Main Condensed Consolidated Financial Statements reported in Euro's

These statements are not part of the original Interim Financial Statements. The original Interim Financial Statements are reported in US Dollars. In case of differences of interpretation between the Financial Statements in US dollars and the Financial Statements in Euros, the Financial Statements in US Dollars will prevail.

Exchange rates (USD:EUR) used:

Statement of income YTD 2019

1.1401

Statement of income YTD 2020

1.1050

Statement of income YTD 2021

1.2087

Balance sheet at December 31, 2020

1.2280

Balance sheet at March 31, 2021

1.1744

Cash flow YTD 2020

1.1050

Cash flow YTD 2021

1.2087

Cash balance as per 1 January 2020

1.1214

Cash balance as per 31 March 2020

1.0976

Cash balance as per 1 January 2021

1.2280

Cash balance as per 31 March 2021

1.1744

Condensed Consolidated Statement of Profit or Loss

in Euros


For the period ended 31 March






Amounts in € '000

YTD 2021

YTD 2020

Revenues

36.042

49.294

Costs of sales

(4.007)

(5.390)

Gross profit

32.035

43.904

Other income

214

241

Research and development

(8.853)

(8.017)

General and administrative

(5.924)

(5.167)

Marketing and sales

(12.274)

(11.515)

Other Operating Costs

(27.051)

(24.699)

Operating profit

5.198

19.446

Fair value loss on revaluation derivatives

25

121

Other finance income

6.750

370

Other finance expenses

(1.322)

(7.525)

Finance cost, net

5.453

(7.034)

Share of net profits in associates using the equity method

(68)

14

Profit before tax

10.583

12.426

Income tax expense

(3.532)

(3.999)

Profit for the year

7.051

8.427

Basic earnings per share (€)

0,011

0,013

Diluted earnings per share (€)

0,011

0,011

Condensed Consolidated Balance Sheet in Euros

As at date shown




Amounts in € '000

March 31, 2021

December 31, 2020

Non-current assets



Intangible assets

76.587

76.615

Property, plant and equipment

11.148

9.956

Right-of-use assets

7.517

7.676

Deferred tax assets

23.467

25.957

Investment accounted for using the equity method

5.722

5.796

Restricted cash

735

415

Total non-current assets

125.176

126.415

Current assets



Inventories

18.533

17.229

Trade and other receivables

28.050

29.236

Restricted cash

820

810

Cash and cash equivalents

175.941

167.068

Total current assets

223.343

214.343

Total assets

348.519

340.758




Equity



Share capital

6.127

6.388

Share premium

382.438

396.799

Legal reserves

9.671

4.341

Accumulated deficit

(239.550)

(258.151)

Shareholders' equity

158.686

149.377

Non-current liabilities



Convertible bonds

120.205

121.927

Lease liabilities

6.594

6.702

Other financial liabilities

161

173

Total non-current liabilities

126.960

128.802

Current liabilities



Convertible bonds

2.607

1.661

Derivative financial liabilities

72

147

Trade and other payables

37.195

38.816

Lease liabilities

1.624

1.598

Other financial liabilities

21.375

20.357

Total current liabilities

62.873

62.579

Total equity and liabilities

348.519

340.758

Condensed Consolidated Statement of Cash Flows in Euros

For the period ended 31 March




Amounts in €'000

YTD 2021

YTD 2020

Profit before tax

10.583

12.426

Non-cash adjustments:



Depreciation, amortisation, impairment

1.706

1.704

Equity settled share-based payments

1.579

563

Fair value gain (loss) loss on revaluation of derivatives

(25)

(121)

Other finance income

(6.750)

(370)

Other finance expenses

1.322

7.582

Share of net profits in associates using the equity method

(68)

14

Other

(906)

(36)

Operating cash flows before changes in working capital

7.443

21.762

Changes in working capital:



Inventories

(503)

(57)

Trade and other receivables

2.450

(4.827)

Payables and other current liabilities

(3.314)

2.499

Restricted cash

(265)

(37)

Total changes in working capital

(1.632)

(2.422)

Interest received

32

370

Income taxes paid

-

-

Net cash flows generated from (used in) operating activities

5.842

19.710

Capital expenditure for property, plant and equipment

(1.618)

(597)

Investment intangible assets

(381)

(190)

Investment associate

329

7

Acquisition of license

(452)

(5.500)

Net cash flows used in investing activities

(2.122)

(6.280)

Repayment on loans and borrowings

-

(49.742)

Payment on contingent consideration

-

(18.135)

Payment of lease liabilities

(458)

(475)

Proceeds of issued convertible bonds

-

125.000

Transaction costs related to issued convertible bond

-

(2.318)

Interests on loans

(1.875)

(346)

Interests on leases

(194)

-

Proceeds of equity and warrants

557

495

Net cash flows generated from (used in) financing activities

(1.972)

54.479

Increase (decrease) of cash

1.751

67.909

Exchange rate effects

7.122

(374)

Cash and cash equivalents at 1 January

167.068

66.299

Total cash and cash equivalents at 31 March

175.941

133.834

Logo - https://mma.prnewswire.com/media/1454235/Pharming_Group_NV_Logo.jpg